Kleniewski J, Donaldson V H
J Lab Clin Med. 1987 Apr;109(4):469-79.
Both kallikrein and plasmin readily released 112,000 and 102,000 molecular weight derivatives from purified human high molecular weight (HMW)-kininogen. In each instance, these early digestion products were composed of disulfide-linked chains of 64,000 and 58,000 molecular weights. Under the experimental conditions used, kallikrein failed to release additional cleavage fragments from HMW-kininogen when it had been previously digested by plasmin, whereas HMW-kininogen pretreated with kallikrein was then cleaved by plasmin into several derivatives of decreasing molecular size. The profound molecular changes induced by plasmin were only accompanied by partial kinin release. Plasmin cleavage dissociated procoagulant activity from at least one antigenic site of HMW-kininogen light chain. Moreover, kinin activity could be released from a cleavage product of HMW-kininogen containing light but not heavy chain antigens, indicating that plasmin had cleaved this kininogen on the N-terminal side of the bradykinin region of the molecule. Cleavage of HMW-kininogen by kallikrein readily released bradykinin, whereas kinin release by plasmin was slower and the cleavage pattern different. It is, therefore, unlikely that plasmin is a major source of bradykinin release in plasma. A method of isolating HMW-kininogen from human plasma is described that provides a homogeneous single band of kininogen, with a recovery of approximately 44% with respect to that in plasma in a period of 5 days.
激肽释放酶和纤溶酶均可轻易地从纯化的人高分子量(HMW)-激肽原中释放出分子量为112,000和102,000的衍生物。在每种情况下,这些早期消化产物均由分子量为64,000和58,000的二硫键连接链组成。在所使用的实验条件下,当HMW-激肽原先前已被纤溶酶消化时,激肽释放酶未能从HMW-激肽原中释放出额外的裂解片段,而用激肽释放酶预处理的HMW-激肽原随后被纤溶酶裂解为几种分子量逐渐减小的衍生物。纤溶酶诱导的深刻分子变化仅伴随着部分激肽释放。纤溶酶裂解使促凝血活性与HMW-激肽原轻链的至少一个抗原位点解离。此外,激肽活性可从含有轻链但不含重链抗原的HMW-激肽原裂解产物中释放出来,这表明纤溶酶已在该激肽原分子缓激肽区域的N端侧裂解了该激肽原。激肽释放酶对HMW-激肽原的裂解很容易释放出缓激肽,而纤溶酶释放激肽的速度较慢且裂解模式不同。因此,纤溶酶不太可能是血浆中缓激肽释放的主要来源。本文描述了一种从人血浆中分离HMW-激肽原的方法,该方法可提供一条均匀的激肽原单带,在5天内相对于血浆中的激肽原回收率约为44%。